Their story
Since 2012, Wandercraft's mission has been to give people with reduced mobility the ability to walk again by creating an innovative, self-stabilizing exoskeleton. This medical equipment incorporates technology designed to promote the cognitive involvement of its user, using the latest advances in bipedal robotics. By enabling upper and lower limb and trunk strengthening exercises, Atalante X meets the needs of therapists and a broad patient population. In 2017, Wandercraft carries out its first clinical trials and obtains CE marking in 2019. In 2022, it launched Atalante X, and in 2023 received FDA approval for marketing in the United States. Wandercraft is now focusing on the design of a personal exoskeleton for everyday use.